ATB Capitol Markets:..what they really said about WillowThe compelling case for an investment in Willow: The potential opportunity associated with the commercialization of cannabinoids is large, and Willow is approaching sales in 2021. In our view, Willow's scientific developments to date and the company's recent capitol raise have significantly de-risked the company's outlook:, 2, We believe Willow is a potential acquisition target should CPG and pharmaceutical companies wish to bring Willow's Expertise in-house due to the company's intellectual property and advanced scientific development.
Think about that:...a potential acquisition target!!!! according to ATB Capitol Markets.